Mind Medicine (MindMed) Inc (NEO:MMED) (OTCQB:MMEDF) told investors Wednesday that it is developing proprietary methods that will personalize psychedelic therapies for each patient.
The New York-based company, along with its Swiss partner the University Hospital Basel, has filed two separate patent applications for technologies that will screen and optimize the dosing of MDMA and LSD.
Research and development surrounding the technology is currently taking place at the University Hospital Basel’s Liechti Lab, which has identified new ways to predict and optimize both the amount of psychedelics needed and the dosing regimen required for therapy.
READ: MindMed to collaborate on study of DMT intravenous dosing regimens with Swiss research partner
"One size never fits all. Healing through psychedelics is a deeply personal process and we believe the personalization of psychedelic therapies is pivotal to the future of this fast growing field of medicine,” MindMed CEO JR Rahn said in a statement.
MindMed and Liechti Lab's analytics method aggregates multiple data and criteria of patients in a pre-dose screening and analysis process, the company told shareholders. The firm is hoping to use this approach to help treat patients who suffer from mental health or addiction disorders, it added.
“Through such analytics and dosing technologies we hope to give patients the best possible outcome from their therapy experiences,” Rahn added.
The approach includes dosing based on solid dose-response data, simple adjustments based on gender and body weight, and pharmacogenetic and personality predictors to optimize dosing to induces specific mental states, according to the technology’s co-founder Dr Matthias Liechti of the University Hospital Basel.
“MindMed has provided the long needed resources to ensure our Lab's inventions can be further developed and hopefully reach the market faster and safer than ever before,” Liechti said in a statement.
The two patent applications cover MDMA dose optimization and LSD dose response. In addition, MindMed has received the exclusive rights from the University Hospital Basel to commercialize the outcome of these patent applications on a global basis.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas